Anthrax acts in surprising ways

In order for the anthrax toxin to enter a cell, its receptor-binding subunit must heptamerize, thus allowing the two enzymatic subunits to join prior to endocytosis. Laurence Abrami and colleagues at the University of Geneva and the National Institute of Allergy and Infectious Diseases recently revealed that endocytosis is regulated by counteracting posttranslational modifications in the receptor itself. Palmitoylation of the receptor's cytoplasmic tail facilitates endocytosis of the tox

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

In order for the anthrax toxin to enter a cell, its receptor-binding subunit must heptamerize, thus allowing the two enzymatic subunits to join prior to endocytosis. Laurence Abrami and colleagues at the University of Geneva and the National Institute of Allergy and Infectious Diseases recently revealed that endocytosis is regulated by counteracting posttranslational modifications in the receptor itself. Palmitoylation of the receptor's cytoplasmic tail facilitates endocytosis of the toxin and receptor by preventing the receptor from being prematurely incorporated into lipid rafts, ubiquitinated, and degraded.1

"This is the first time that the relationship between palmitoylation, recruitment to lipid raft, and ubiquitination has been clarified," says Faculty of 1000 reviewer Giampietro Schiavo, a cell biologist at the London Research Institute. "The authors find that palmitoylation prevents the receptors' entry into lipid rafts. This mechanism was totally unexpected. The general view was exactly the opposite: That palmitoylation would mediate targeting to lipid ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies